Next Article in Journal
Mechanism of the Affinity-Enhancing Effect of Isatin on Human Ferrochelatase and Adrenodoxin Reductase Complex Formation: Implication for Protein Interactome Regulation
Next Article in Special Issue
Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines
Previous Article in Journal
Analysis of Spatio-Temporal Transcriptome Profiles of Soybean (Glycine max) Tissues during Early Seed Development
Previous Article in Special Issue
Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors

Oncolytic Virotherapy in Glioma Tumors

Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, 28668 Madrid, Spain
Facultad de Medicina, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, 28668 Madrid, Spain
Centre for Metabolomics and Bioanalysis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, 28668 Madrid, Spain
Faculty of Experimental Sciences, Universidad Francisco de Vitoria, 28223 Madrid, Spain
Brain Tumor Laboratory, Fundación Vithas, Grupo Hospitales Vithas, 28043 Madrid, Spain
Authors to whom correspondence should be addressed.
These authors collaborated equally on this manuscript.
Int. J. Mol. Sci. 2020, 21(20), 7604;
Received: 27 August 2020 / Revised: 8 October 2020 / Accepted: 12 October 2020 / Published: 14 October 2020
(This article belongs to the Special Issue Oncolytic Virotherapy)
Glioma tumors are one of the most devastating cancer types. Glioblastoma is the most advanced stage with the worst prognosis. Current therapies are still unable to provide an effective cure. Recent advances in oncolytic immunotherapy have generated great expectations in the cancer therapy field. The use of oncolytic viruses (OVs) in cancer treatment is one such immune-related therapeutic alternative. OVs have a double oncolytic action by both directly destroying the cancer cells and stimulating a tumor specific immune response to return the ability of tumors to escape the control of the immune system. OVs are one promising alternative to conventional therapies in glioma tumor treatment. Several clinical trials have proven the feasibility of using some viruses to specifically infect tumors, eluding undesired toxic effects in the patient. Here, we revisited the literature to describe the main OVs proposed up to the present moment as therapeutic alternatives in order to destroy glioma cells in vitro and trigger tumor destruction in vivo. Oncolytic viruses were divided with respect to the genome in DNA and RNA viruses. Here, we highlight the results obtained in various clinical trials, which are exploring the use of these agents as an alternative where other approaches provide limited hope. View Full-Text
Keywords: glioma; oncolytic virus; glioblastoma; virotherapy glioma; oncolytic virus; glioblastoma; virotherapy
Show Figures

Figure 1

MDPI and ACS Style

Rius-Rocabert, S.; García-Romero, N.; García, A.; Ayuso-Sacido, A.; Nistal-Villan, E. Oncolytic Virotherapy in Glioma Tumors. Int. J. Mol. Sci. 2020, 21, 7604.

AMA Style

Rius-Rocabert S, García-Romero N, García A, Ayuso-Sacido A, Nistal-Villan E. Oncolytic Virotherapy in Glioma Tumors. International Journal of Molecular Sciences. 2020; 21(20):7604.

Chicago/Turabian Style

Rius-Rocabert, Sergio, Noemí García-Romero, Antonia García, Angel Ayuso-Sacido, and Estanislao Nistal-Villan. 2020. "Oncolytic Virotherapy in Glioma Tumors" International Journal of Molecular Sciences 21, no. 20: 7604.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop